Table 3.

Differences in use of antihypertensive medications, pre-guideline (2016–2017) to post-guideline (2018–2019) visits

Characteristic	Not reclassified (SBP 120–129)			Reclassified to stage 1 hypertension (SBP 130–139)			Reclassified to stage 2 hypertension (SBP 140–159)
	Pre-Guideline	Post-Guideline	p-value for difference	Pre-Guideline	Post-Guideline	p-value for difference	Pre-Guideline	Post-Guideline	p-value for difference
Any antihypertensivea	74.8%	74.9%	0.86	77.3%	78.4%	0.25	78.3%	81.4%	<0.001
First-line antihypertensiveb,c	64.5%	60.4%	<0.001	64.9%	66.7%	0.10	68.3%	70.1%	0.08
Number of antihypertensivesb			0.003			0.09			0.002
0	25.6%	25.9%	N/A	23.1%	21.9%	N/A	22.5%	19.8%	N/A
1	22.0%	24.0%	N/A	23.8%	24.6%	N/A	21.7%	23.4%	N/A
2	23.9%	25.0%	N/A	30.1%	28.1%	N/A	27.9%	26.5%	N/A
3+	28.6%	25.1%	N/A	23.0%	25.5%	N/A	27.9%	30.2%	N/A

^aBased on self-report of taking an antihypertensive or objective antihypertensive medication use

^bBased on objective medication data only

^cDefined as angiotensin converting enzyme inhibitor, angiotensin receptor blocker, dihydropyridine calcium channel blocker, or thiazide diuretic

Note: Boldface indicates statistical significance. N/A: not applicable; SBP: systolic blood pressure